2025 AQUA Registry QCDR measures

2025 QCDR Measure ID	Measure Title	Measure Description	Denominator	Numerator	Denominator Exclusions	Denominator Exceptions	Numerator Exclusions	CBE ID Number	High-Priority Measure	Measure Type	Includes Telehealth	Inverse Measure	Proportional Measure	Variable Measure	Ratio Measure	Number of performance rates to be calculated and submitted	Risk Adjusted Status	MIPS Reporting Options	Care Setting
AQUAS	Hospital Admissions or Infectious Complications Within 30 days of Prostate Biopsy	Percordage of patients with urinary retention, infection, inpatient consultation, or hospital admission for infection or sepsis within 30 days of undergoing a prostate biopsy		Patients with uniany retention, infection or new artibiotic prescription at least 24 hours after, and within 30 days of, prostate biopsy, or an inpatient consultation within 30 days of prostate biopsy, or infection or sepsis requiring hospitalization within 30 days of prostate biopsy	None	None	None	N/A	Yes	Outcome	No	Yes	Yes	No	No	1	No	MVP, Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Hospital
AQUA14	Stones: Repeat Shock Wave Lithotripsy (SWL) Within 6 Months of Initial Treatment	Percentage of patients who underwent repeat Shock Wave Lithotripsy within 6 months of initial procedure	Patients 18 years and older who underwent an SWL procedure for the treatment of stones	Patients who underwent an ipsilateral SWL procedure within 6 months	None	None	None	N/A	Yes	Outcome	No	Yes	Yes	No	No	1	No	MVP, Traditional MIPS	Ambulatory Care: Hospital; Ambulatory Surgical Center; Hospital; Office Based Surgery Center
AQUA15	Stones: Urinalysis or Urine Culture Performed Before Surgical Stone Procedures	Percentage of patients with a documented urinalysis or urine culture within 14 days prior to surgical stone procedures	Patients 18 years and older who underwent a surgical procedure for the treatment of stones	Patients with documented urinalysis or urine culture within 14 days prior to surgery	None	None	None	N/A	Yes	Process	No	No	Yes	No	No	1	No	MVP, Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Outpatient Services
AQUA16		Percentage of patients with T1 disease who had a second transurethral resection of bladder tumor (TURBT) within 6 weeks of the initial TURBT	Patients 18 years and older diagnosed with clinical stage T1 bladder cancer	Patients with T1 disease who had a second TURBT within 6 weeks of the initial TURBT	None	Onset of systemic chemotherapy or radical cystectomy within 12 weeks of diagnosis	None	N/A	No	Process	No	No	Yes	No	No	1	No	MVP, Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Ambulatory Care: Hospital; Ambulatory Surgical Center: Hospital
AQUA35	Non-Muscle Invasive Bladder Cancer: Initial Management/Surveillance for Non-Muscle Invasive Bladder Cancer	Percentage of patients with appropriate initial management/surveillance after initial diagnosis of non-muscle invasive bladder cancer	cancer who underwent initial TURBT	Patients who had 2 or more surveillance cystoscopies or who had a repeat TURBT and 1 or more surveillance cystoscopies within 14 months after initial TURBT	None	Onset of systemic chemotherapy or radical cystectomy within 12 weeks of bladder cancer diagnosis	None	N/A	No	Process	No	No	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Ambulatory Care: Hospital; Ambulatory Surgical Center; Hospital
AQUA36	Prostate Cancer: Confirmation Biopsy in Newly Diagnosed Patients on Active Surveillance	Percentage of newly diagnosed low risk patients on active surveillance who receive confirmation biopsy within 24 months of diagnosis	Patients aged 30-75 with new diagnosis of low risk prostate cancer who are on active surveillance	Patients who underwent a second biopsy within 24 months after date of diagnosis	None	Treatment for prostate cancer within 12 months post-diagnosis	None	N/A	No	Process	No	No	Yes	No	No	1	No		Ambulatory Care: Clinician Office/Clinic; Ambulatory Care: Hospital; Ambulatory Surgical Center: Hospital Outpatient
MUSIC4	Prostate Cancer: Active Surveillance/Watchful Waiting for Newly Diagnosed Low Risk Prostate Cancer Patients	Proportion of patients newly diagnosed with low-risk prostate cancer managed with active surveillance or watchful waiting	Newly diagnosed low-risk prostate cancer patients age 30 or older	Patients on active surveillance or watchful waiting (no evidence of radical therapy post-diagnosis)	None	None	None	N/A	Yes	Process	No	No	Yes	No	No	1	No	MVP, Traditional MIPS	Ambulatory Care: Clinician Office/Clinic

Cancer Patients

AQUI measures 2024 American Unickgical Association. All Rights Reserved.

MUSIC4 (2011 The Regents of the University of Michigan. Criginal MUSIC measure developed by the University of Michigan as part of the Michigan Unological Surgery Improvement Collaborative. All Rights Reserved.